The Duke Interstitial Lung Disease Program consists of a group of nationally and internationally known pulmonologists, radiologists, pathologists, and thoracic surgeons offering expertise in the diagnosis and treatment of patients with interstitial lung disease (ILD).
ILD includes a heterogeneous group of respiratory disorders usually of unknown cause, characterized by inflammatory or fibrotic infiltration of the alveolar walls and spaces. Advances in our understanding of events leading to lung injury and the response to that damage have resulted in improvements in the diagnosis and treatment of a number of these disorders.
Examples of interstitial lung disease include idiopathic pulmonary fibrosis (and its variants), nonspecific interstitial pneumonia, sarcoidosis, hypersensitivity pneumonitis, eosinophilic pneumonia, cryptogenic organizing pneumonia, and ILD associated with connective tissue diseases.
Duke has a world famous Lung Transplant Program, and we routinely consider patients with progressive ILD for transplant if appropriate. Duke is well qualified to offer state-of-the-art, comprehensive care to patients with severe ILD.
Scientists at Duke are striving to improve our understanding of the molecular mechanisms leading to ILD. The ILD Clinic at Duke is participating in several multi-center clinical trials to test new and promising medications for treatment of IPF.
Multidisciplinary ILD Board and Working Group
Each week, new ILD cases are presented. Clinical data, radiographic images and biopsy specimens (when available) are reviewed by a team of pulmonologists, radiologists, and pathologists with specific expertise in the field of ILD. The goal of this conference is to improve diagnostic accuracy through an interactive and dynamic approach. Treatment and management plans are also discussed.
ILD Clinic Team
ILD Research Trials Coordinator
Rose Marie Smigla, RN, BSN